The emerging roles of exosomes in anti-cancer drug resistance and tumor progression: An insight towards tumor-microenvironment interaction

Jena, Bikash Chandra

doi:10.1016/j.bbcan.2020.188488

Cited by 51 publications

(45 citation statements)

References 172 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Until recently, CAFs have been considered to induce cancer progression and chemoresistance ( Olumi et al, 1999 ; Orimo et al, 2005 ; Jena et al, 2020 ; Jena and Mandal, 2021 ). However, studies using single-cell transcriptome and proteome analyses indicated the presence of functionally and molecularly heterogeneous CAFs, including pCAFs and rCAFs.…”

Section: Discussionmentioning

confidence: 99%

Roles of the Mesenchymal Stromal/Stem Cell Marker Meflin/Islr in Cancer Fibrosis

Takahashi

Kobayashi

Mizutani

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Fibroblasts synthesise the extracellular matrix (ECM) such as collagen and elastin, the excessive accumulation of which can lead to fibrosis and organ dysfunction under pathological conditions. Cancer-associated fibroblasts (CAFs) are major constituents of the tumour microenvironment (TME) that accompany the desmoplastic reaction responsible for anti-cancer treatment resistance. Thus, it is important to dissect the roles of CAFs in the TME to develop new therapeutic strategies for refractory cancers. Recent progress in the studies of CAF biology suggests that the functions of CAFs are complicated and that they are composed of functionally distinct populations, including cancer-promoting CAFs (pCAFs) and cancer-restraining CAFs (rCAFs). We recently identified a new cell surface marker for rCAFs in pancreatic and colon cancers, designated as Meflin (mesenchymal stromal cell- and fibroblast-expressing Linx paralogue)/Islr (immunoglobulin super family containing leucine-rich repeat). Based on the distribution of Meflin/Islr-positive cells, we also considered it a specific candidate marker for mesenchymal stroma/stem cells. Meflin/Islr-positive CAFs have been shown to suppress cancer progression by being involved in regulating collagen structures and BMP signalling in the TME. This review describes the function of Meflin/Islr in cancer fibrosis as well as in cardiac and lung fibrosis and its potential in the development of new cancer therapeutics.

show abstract

Section: Discussionmentioning

confidence: 99%

Roles of the Mesenchymal Stromal/Stem Cell Marker Meflin/Islr in Cancer Fibrosis

Takahashi

Kobayashi

Mizutani

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Secretomes, including cytokines, growth factors, extracellular nucleic acids, and extracellular vesicles (EVs), either from cancer cells or from stromal cells, confer drug resistance [ 147 , 340 , 341 , 342 , 343 ]. For example, HGF was identified as a resistant growth factor in a co-culture screening of 23 stromal cell types with 45 cancer cell lines against 35 anticancer drugs [ 344 ].…”

Section: Resistance To Anti-egfr Therapeuticsmentioning

confidence: 99%

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer

You

Cho

et al. 2021

Pharmaceuticals

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a subset of breast cancer with aggressive characteristics and few therapeutic options. The lack of an appropriate therapeutic target is a challenging issue in treating TNBC. Although a high level expression of epidermal growth factor receptor (EGFR) has been associated with a poor prognosis among patients with TNBC, targeted anti-EGFR therapies have demonstrated limited efficacy for TNBC treatment in both clinical and preclinical settings. However, with the advantage of a number of clinically approved EGFR inhibitors (EGFRis), combination strategies have been explored as a promising approach to overcome the intrinsic resistance of TNBC to EGFRis. In this review, we analyzed the literature on the combination of EGFRis with other molecularly targeted therapeutics or conventional chemotherapeutics to understand the current knowledge and to provide potential therapeutic options for TNBC treatment.

show abstract

“…Exosomes may clear drugs and metabolites from the tumor cells and consequently mitigate the therapeutic effect of drugs through various transporters. 91 Meena et al 92 indicated that paclitaxel promoted exosome releasing from HCC cells, which conferred drug resistance to ajacent cells as the exosomes transported the drug out of the cells. This process was partly mediated by the ATP-binding cassette (ABC) transporter family.…”

Section: Chemoresistance and Exosome-related Drug-resistance Of Hccmentioning

confidence: 99%

“…In particular, ABCB1 expression is upregulated in HCC cells that are resistant to paclitaxel, epirubicin, and doxorubicin. 91 The other efflux pumps ABCB2 and ABCA3 also contribute to chemoresistance by transferring exosomal drugs. 94 This is a potential novel mechanism of chemoresistance in cancer cells.…”

Section: Chemoresistance and Exosome-related Drug-resistance Of Hccmentioning

confidence: 99%

Current perspectives on exosomes in the diagnosis and treatment of hepatocellular carcinoma (review)

Xue

Han

Liu

et al. 2021

Cancer Biology & Therapy

View full text Add to dashboard Cite

The prognosis of hepatocellular carcinoma (HCC), a malignant tumor, is poor. Tumor recurrence and metastasis are the major challenges for the treatment of HCC. Various studies have demonstrated that exosomes, which are loaded with various biomolecules including nucleic acids, lipids, and proteins are involved in the recurrence and metastasis of HCC. Additionally, exosomes mediate various biological processes, such as immune response, cell apoptosis, angiogenesis, thrombosis, autophagy, and intercellular signal transduction. In cancer, exosomes regulate cancer cell differentiation, development, and drug resistance. Circular RNAs, microRNAs, and proteins in the exosomes can serve as early diagnostic and prognostic markers for HCC. As exosomes are characterized by low immunogenicity and high stability in the tissues and circulation, they can be used to deliver the drugs in cancer therapies.

show abstract

The emerging roles of exosomes in anti-cancer drug resistance and tumor progression: An insight towards tumor-microenvironment interaction

Cited by 51 publications

References 172 publications

Roles of the Mesenchymal Stromal/Stem Cell Marker Meflin/Islr in Cancer Fibrosis

Roles of the Mesenchymal Stromal/Stem Cell Marker Meflin/Islr in Cancer Fibrosis

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer

Current perspectives on exosomes in the diagnosis and treatment of hepatocellular carcinoma (review)

Contact Info

Product

Resources

About